Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
Key Highlights
- ➤PTC-2105 preserved Rotarod performance versus a 76% vehicle decline at Week 16
- ➤PTC-2105 reduced rat fat mass 14.5% versus 8.2% with vehicle at Week 8
- ➤First-in-human PTC-2105 trials targeted for 2027, subject to IND clearance
- ➤Pulmatrix merger approved; combined company expected to trade under MTXL
- ➤Non-GLP rat and dog toxicology studies began ahead of GLP toxicology
Expert Statements
Kevin Slawin, Founder and Chief Executive Officer of Eos SENOLYTIX
“This preclinical study in aging rats was designed to help evaluate our licensed MitoXcel™ platform technology and its novel mitochondria-targeted geropeptides as we move toward first-in-human clinical trials”
Kevin Slawin, Founder and Chief Executive Officer of Eos SENOLYTIX
“These early results, now in a second preclinical model, strengthen our confidence that the benefits we have seen in preclinical studies may translate into meaningful clinical improvements for participants in our trials. We are now conducting IND-enabling studies of PTC-2105, our lead clinical candidate, for older adults with sarcopenia and sarcopenic obesity.”
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling Development Ahead of Planned First-in-Human Trials
HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today announced early interim results from a study of its lead MitoXcel™ geropeptide, PTC-2105, in aged rats, conducted at the BIO-VITAL Program Preclinical Testing Core facility of the Albert Einstein College of Medicine (“Einstein”) in the Bronx, New York, under a fee-for-service agreement. According to the Company, in the oldest rats studied (approximately 24 to 26 months of age at enrollment), PTC-2105 administered subcutaneously (“SC”) once weekly preserved Rotarod and treadmill motor performance at Week 16 and increased fat-mass loss at Week 8, compared with vehicle in small interim groups. The findings are consistent with those previously observed in naturally aged mice and add second-species data to support the Company’s Investigational New Drug (“IND”)-enabling program, with first-in-human trials targeted for 2027, subject to IND clearance.
Get started
Create a free account to read the full story.